Altium Capital Management LP Syndax Pharmaceuticals Inc Transaction History

Altium Capital Management LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$15.23 - $22.47 $1.64 Million - $2.43 Million	-108,000 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$13.87 - $19.8 $1.5 Million - $2.14 Million	108,000 New	108,000 $1.88 Million
Q2 2021 Aug 13, 2021	SELL	$13.42 - $25.18 $3.4 Million - $6.38 Million	-253,448 Closed	0 $0
Q1 2021 May 06, 2021	SELL	$19.28 - $24.59 $195,653 - $249,539	-10,148 Reduced 3.85%	253,448 $5.67 Million
Q4 2020 Feb 16, 2021	BUY	$15.1 - $26.44 $3.98 Million - $6.97 Million	263,596 New	263,596 $5.86 Million

228

88.4M

1.01M

692K

Ticker SNDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,565,200
Market Cap $796M
Description
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...

Get notified when there are updates to the investment portfolio of Altium Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Altium Capital Management LP with notifications on news.